ANI Pharmaceuticals, Inc. (ANIP)
ANI Pharmaceuticals, Inc. (ANIP) is a pharmaceutical company that develops, manufactures, and markets a broad portfolio of generic and branded prescription drugs. Founded in 2007 and headquartered in Schaumburg, Illinois, the company focuses on producing high-quality, affordable medications across various therapeutic areas, including CNS, cardiovascular, and women's health. ANI emphasizes leveraging its formulation expertise and a robust pipeline to meet the needs of healthcare providers and patients.
Company News
CG Oncology announced that its leadership will participate in two upcoming investor conferences in September 2025, presenting at the Cantor Global Healthcare Conference and Morgan Stanley 23rd Annual Global Healthcare Conference.
Cg Oncology reported a wider net loss in Q2 2025, with no revenue and increased R&D expenses. The company continues developing a gene therapy for bladder cancer and plans to submit a Biologics License Application in Q4 2025.
ANI Pharmaceuticals reported strong Q4 results, with adjusted EPS and sales beating estimates. The company raised its 2025 guidance for revenue and adjusted EPS, driven by growth in its Cortrophin Gel, generics, and branded products.
Agenus Inc. (AGEN) shares plunged 58.8% after the FDA discouraged the accelerated approval pathway for the company's immunotherapy combination botensilimab (BOT) and balstilimab (BAL) in relapsed/refractory microsatellite stable colorectal cancer. The FDA cited concerns that the observed objective response rate might not translate to a survival benefit.
